| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/01/2006 | CN1239157C Preparations stimulating nail growth |
| 02/01/2006 | CN1239153C Transdermal therapeutic system based on polyacrylate-contact-bonding adhesives without functional groups |
| 02/01/2006 | CN1239152C Therapeutic formulation for administering tolterodine with controlled release |
| 02/01/2006 | CN1239151C Tablets quickly disintegrating in oral cavity |
| 02/01/2006 | CN1239150C Nano grade vitamin micro emulsion and its preparing method |
| 02/01/2006 | CN1239149C Pharmaceutical formulation having masked taste and method for production thereof |
| 02/01/2006 | CN1239133C Medical device |
| 02/01/2006 | CN1239103C Nutritious health care food and preparation method thereof |
| 02/01/2006 | CN1239091C Nano grade condiment micro emulsion and its preparing method |
| 01/31/2006 | US6992233 Material delivery system |
| 01/31/2006 | US6992218 Method for obtaining aqueous formulations of oxidation-sensitive active principles |
| 01/31/2006 | US6992194 suspending crystal strutured or amorphous lipitor in diluents comprising alcohols and/or water mixtures to cause conversion, then separating the diluents; monodispersity |
| 01/31/2006 | US6992066 Povidone-containing carriers for polypeptide growth factors |
| 01/31/2006 | US6992065 Sustained release formulations |
| 01/31/2006 | US6991817 Acid-modified arabinogalactan protein composition |
| 01/31/2006 | US6991816 Aqueous solution of flavonoids and anthocyanins |
| 01/31/2006 | US6991809 Particles with improved solubilization capacity |
| 01/31/2006 | US6991808 Impermeable cup or coating layer is adhered to an uncured suture tab and covered with permeable polymer (polyvinyl acetate); for use in treatment of retinitits and glaucoma |
| 01/31/2006 | US6991807 Four different dosage forms, two antibiotics inhibiting protein and non-protein synthesis, one comprising immediate release and sustained release, the other three has sustained release forms, twenty-four hour period; bacterial infections |
| 01/31/2006 | US6991806 Pharmaceutical compositions comprising ibuprofen and domperidone |
| 01/31/2006 | US6991805 Temperature sensitive control of liposome-cell adhesion |
| 01/31/2006 | US6991804 Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
| 01/31/2006 | US6991803 Inorganic shaped bodies and methods for their production and use |
| 01/31/2006 | US6991802 Multilayered material bearing a biologically active agent and the preparation thereof |
| 01/31/2006 | US6991801 topical veterinary formulations, such as spot-on and pour-on formulations, which are used in treating, controlling and preventing of endo and ectoparasite infections in warm-blooded animals or birds, such as horses, cattle, sheep, pigs and pets |
| 01/31/2006 | US6991800 containing an echinocandin antifungal compound and an aqueous solvent, wherein the formulation includes about 20% w/v ethanol; extended shelf life, improved solubility |
| 01/31/2006 | US6991789 modulating fusion between a lysosome and an endosome that carries the toxin in the cell; locally co-administering a toxin and a lysosome-endosome fusion inhibitor to a group of muscles of the patient in need thereof |
| 01/31/2006 | US6991779 Biologically active molecules encapsulated in self-assembling, diketopiperazine microspheres, TECHNOSPHEREs tm ) and methods for making and administering such compositions are described herein. The compositions can be used to immunize individuals |
| 01/31/2006 | US6991776 Halogenated xanthene or halogenated xanthene derivative; cancer treatment |
| 01/31/2006 | US6991095 Packaging bag for plaster and packaged plaster |
| 01/31/2006 | CA2490335C Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| 01/31/2006 | CA2371836C Porous drug matrices and methods of manufacture thereof |
| 01/31/2006 | CA2171627C Rectally-administered, epileptic-seizure-inhibiting composition |
| 01/31/2006 | CA2150803C Controlled release growth hormone containing microspheres |
| 01/31/2006 | CA2133012C Pulverulent mannitol of moderate friability and process for its preparation |
| 01/31/2006 | CA2101851C Aerosol hair spray |
| 01/26/2006 | WO2006010083A2 Biodegradable nanoparticles |
| 01/26/2006 | WO2006010066A2 Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| 01/26/2006 | WO2006009825A1 Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
| 01/26/2006 | WO2006009801A2 Compositions and methods for treating central precocious puberty |
| 01/26/2006 | WO2006009769A1 Modified release formulation of memantine |
| 01/26/2006 | WO2006009764A1 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers |
| 01/26/2006 | WO2006009737A1 Oral care film |
| 01/26/2006 | WO2006009679A2 Oral care compositions |
| 01/26/2006 | WO2006009559A1 Delivery of bioactive substances to target cells |
| 01/26/2006 | WO2006009022A1 Liposome-containing x-ray radiopaque dye and process for producing the same |
| 01/26/2006 | WO2006008757A2 Stabilized pharmaceutical compositions of pravastatin |
| 01/26/2006 | WO2006008640A1 Non-aqueous suspension containing a drug having an unpleasant taste |
| 01/26/2006 | WO2006008517A2 Use of dry powder compositions for pulmonary delivery |
| 01/26/2006 | WO2006008401A2 Composition containing a photosynthetic marine and/or fresh-water microorganism culture medium and/or |
| 01/26/2006 | WO2006008320A2 Device for transdermal delivery of active principles |
| 01/26/2006 | WO2006008173A2 Pharmaceutical formulations for inhalation |
| 01/26/2006 | WO2006007881A2 New pharmaceutical compositions based on fluorenecarboxyclic acid esters and soluble tnf receptor fusion proteins |
| 01/26/2006 | WO2006007839A1 Composition comprising minerals and uses thereof |
| 01/26/2006 | WO2006007780A1 Injectable bone-repairing bioactive material capable of forming gel and its preparation method |
| 01/26/2006 | WO2005112996B1 1,4 o-linked saccharose derivatives for stabilizing antibodies or antibody derivatives |
| 01/26/2006 | WO2005110002A3 Anti-inflammatory and anticeptic suppository exhibiting a regeneration effect |
| 01/26/2006 | WO2005094384A3 Methods and compositions for treatment of ion imbalances |
| 01/26/2006 | WO2005079747A8 Pharmaceutical preparation for the oral cavity |
| 01/26/2006 | WO2005070467A3 Method of protecting sensitive molecules from a photopolymerizing environment |
| 01/26/2006 | WO2005070394A3 Ternary non-lamellar lipid compositions |
| 01/26/2006 | WO2005070392A3 Non-lamellar compositions of dioleoyl phosphatidylethanolamine and polysorbate 80 |
| 01/26/2006 | WO2005067499A3 Method and device for topical delivery of therapeutic agents to the skin |
| 01/26/2006 | WO2005060550A3 Methods and compositions for treating skin wounds |
| 01/26/2006 | WO2005055979A3 Ph triggerable polymeric particles or films containing a poly (beta-amino ester) |
| 01/26/2006 | WO2005048931A3 Dissolving thin film xanthone supplement |
| 01/26/2006 | WO2005048927A3 Methods and reagents for the treatment of inflammatory disorders |
| 01/26/2006 | WO2005002542A3 Nanoparticulate meloxican formulations |
| 01/26/2006 | WO2003079990A3 Microencapsulation using ultrasonic atomizers |
| 01/26/2006 | US20060020292 Therapy programming guidance based on stored programming history |
| 01/26/2006 | US20060020290 Medical device with memory upload trigger |
| 01/26/2006 | US20060020158 Method of drug delivery to interstitial regions of the myocardium |
| 01/26/2006 | US20060020130 Spraying a cefuroxime axetil solution via an atomizer into a stirred reactor containing an antisolvent to precipitate and crystallize the cefuroxime axetil into a slurry via antisolvent recrystallization; filtering and drying to obtain amorphous cefuroxime axetil powder; particle size of 20nm-30mu m. |
| 01/26/2006 | US20060020040 Bupropion hydrochloride solid dosage forms |
| 01/26/2006 | US20060019970 Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites |
| 01/26/2006 | US20060019904 Composition for promoting lacrimal secretion |
| 01/26/2006 | US20060019903 Compositions and methods for treating precocious puberty |
| 01/26/2006 | US20060019877 Hasylated polypeptides |
| 01/26/2006 | US20060019870 Apoprotein cochleate compositions |
| 01/26/2006 | US20060019239 enhancing the immunogenicity of a vaccine against Bacillus anthracis by administering an oligodeoxynucleotide with a vaccine against Bacillus anthracis; Anthrax Vaccine Adsorbed (AVA) vaccine |
| 01/26/2006 | US20060018984 Intravaginal washing agent |
| 01/26/2006 | US20060018972 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| 01/26/2006 | US20060018971 Nucleic acid microspheres, production and delivery thereof |
| 01/26/2006 | US20060018970 Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
| 01/26/2006 | US20060018969 Pharmaceutical dose form and method of making the same |
| 01/26/2006 | US20060018968 Use of polyethylene glycol based fluidized polymer suspension in functional systems |
| 01/26/2006 | US20060018967 Method for treating pipelines |
| 01/26/2006 | US20060018966 Antimicrobial mesoporous silica nanoparticles |
| 01/26/2006 | US20060018965 Solid oral dosage form containing seamless microcapsules |
| 01/26/2006 | US20060018964 Pharmaceutical formulation and process for its preparation |
| 01/26/2006 | US20060018963 tablet core, which comprises at least 70% venlafaxine besylate and coating over tablet core which comprises an ammonio methacrylate copolymer component, wherein coating is in an amount within the range of 3% to 25% of the weight oftablet core |
| 01/26/2006 | US20060018962 Sustained release formulation of tramadol |
| 01/26/2006 | US20060018961 Compression formed preparation and method for manufacturing same |
| 01/26/2006 | US20060018960 solid oral dosage form comprising about 83 to 332 mg of aliskiren or a hemi-fumarate salt thereof; in vitro dissolution profile of more than 46% by weight of the oral dosage form; renin inhibitor; antihypertensives for treating congestive heart failure; industrial scale manufacture |
| 01/26/2006 | US20060018959 Solid drug for oral use |
| 01/26/2006 | US20060018958 Soft gel formulation includes Coenzyme Q10, Vitamin E, beta-carotene, bee's wax, medium chain triglycerides available as MCT Myglyol S12, and rice bran oil formulated to maximize the body's absorption |
| 01/26/2006 | US20060018957 Pharmaceutical dosage forms including rasagiline |
| 01/26/2006 | US20060018956 Dermal application system for aminolevulinic acid-derivatives |
| 01/26/2006 | US20060018953 Eyelid margin wipes comprising chemical means for temperature adjustment |
| 01/26/2006 | US20060018952 Molecular reactive chitosan finishing agent used for textile |